<DOC>
	<DOC>NCT03050710</DOC>
	<brief_summary>In this study, eligible subjects with moderate to severe nasolabial folds will be treated with Princess® VOLUME Lidocaine and will return for follow-up assessments 2, 4, 24 and 36 weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate by the investigator.</brief_summary>
	<brief_title>Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Male or female 18 years of age or older Presence of two fully visible, approximately symmetrical nasolabial folds, with each of the folds, scored 23 according to the 5grade Nasolabial Folds Severity Rating Scale Healthy skin in the facial area and free of diseases that could interfere in cutaneous aging evaluation Willingness to abstain from any aesthetic or surgical procedures in the treatment area for the duration of the clinical investigation Written signed and dated informed consent Pregnancy, lactation, planned pregnancy or unwillingness to use contraception at any time during the study (for women of childbearing potential only) History of allergic reaction or hypersensitivity to hyaluronic acid, lidocaine, or any amidebased anesthetic Presence of silicone implant or another nonabsorbable substance (permanent fillers) in the nasolabial region Presence of infectious, inflammatory, or proliferative lesions in the nasolabial region Cutaneous lesions in the treatment area History or presence of any autoimmune or connective tissue disease, or current treatment with immune therapy Use of anticoagulant, antiplatelet or thrombolytic medication Any medical condition which, in the investigator's opinion, prohibits the inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>